Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 18/20 | 0.51 |
| ▸ | GPR4 | P46093 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984214 | 0.90 | ACKR3 (0.49) | P2RY12GPR4ACKR3 | |
| SCHEMBL12544672 | 0.89 | GPR4 (0.51) | GPR4ACKR3 | |
| SCHEMBL2909201 | 0.83 | P2RY12 (0.49) | P2RY12 | |
| SCHEMBL985081 | 0.83 | PPARG (0.56) | P2RY12 | |
| SCHEMBL1438607 | 0.79 | GPR4 (0.50) | GPR4ACKR3 | |
| SCHEMBL18135536 | 0.77 | KCNA5 (0.64) | — | |
| SCHEMBL981734 | 0.76 | MAPT (0.48) | P2RY12 | |
| SCHEMBL12693643 | 0.75 | HRH2 (0.48) | — | |
| SCHEMBL1743929 | 0.73 | TLR8 (0.50) | GPR4ACKR3 | |
| SCHEMBL1437414 | 0.73 | GPR4 (0.50) | GPR4ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2217606-A1 | SOLUBILIZED THIAZOLOPYRIDINES | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRT3, SIRT1, SIRT2 | P2RY12 1151/4885GPR4 2601/4885ACKR3 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.